Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Correlates to the Clinical Diagnosis of Premature Ejaculation: Results From a Large Observational Study of Men and Their Partners
Rosen, Raymond C., McMahon, Chris G., Niederberger, Craig , Broderick, Gregory A. , Jamieson, Carol , Gagnon, Dennis D.

Mayo Clinic

Journal of Urology | February 11, 2007 | Volume: 177 | Issue: 3 | Pages: 1059-1064

10.1016/j.juro.2006.10.044 | PMID 17296411 Get It

Randomized Phase II Trial of Paclitaxel Plus Carboplatin or Gemcitabine Plus Cisplatin in Eastern Cooperative Oncology Group Performance Status 2 Non–Small-Cell Lung Cancer Patients: ECOG 1599
Langer, Corey J. , Li, Sigui, Schiller, Joan H. , Tester, William , Rapoport, Bernardo L. , Johnson, David H.

Mayo Clinic

Journal of Clinical Oncology | February 2, 2007 | Volume: 25 | Issue: 4 | Pages: 418-423

10.1200/jco.2005.04.9452 | PMID 17264337 Get It

Purpose Appropriate therapy for Eastern Cooperative Oncology Group (ECOG) performance status (PS) -2 patients with advanced non–small-cell lung cancer (NSCLC) remains challenging. PS-2 patients on ECOG 1594 had a median survival (MS) of only 4.1 months and 1-year overall survival (OS) of 19%. Three percent had grade 5 toxicity. Patients and Methods ECOG 1599, the first PS 2–specific, US cooperative group trial for treatment-naïve advanced NSCLC, randomly assigned patients to dose-attenuated carboplatin/paclitaxel (the least toxic regimen in ECOG 1594) or gemcitabine/cisplatin (which yielded an MS of 7.9 months in PS-2 patients). Patients received either carboplatin (area under the concentration-time curve, 6) and paclitaxel 200 mg/m2 every 3 weeks (CbP) or gemcitabine 1 g/m2 days 1 and 8 and cisplatin 60 mg/m2 day 1 every 3 weeks (CG). Results One hundred three patients were enrolled; 100 proved eligible. Median age was 66 years; 46% had at least 5% weight loss; 88% had stage IV or recurrent disease. Median number of cycles administered was three per arm. CbP featured more grade 3 neutropathy (10% v 0%) and more grade ≥ 3 neutropenia (59% v 33%), whereas CG yielded more grade ≥ 3 thrombocytopenia (33% v 14%), more grade ≥ 3 fatigue (22% v 14%), and more grade ≥ 1 creatinine elevations (43% v 6%). One grade 5 toxicity, confined to the CbP arm, occurred. Response rate, time to progression, MS, and 1-year OS rates for CG and CbP, were 23%, 4.8 months, 6.9 months, and 25%, and 14%, 4.2 months, 6.2 months, and 19%, respectively. Conclusion Platinum-based combination chemotherapy for PS-2 patients with NSCLC is feasible with acceptable toxicity, but survival in these patients remains inferior to that of PS-0 to -1 patients.
Acquired Long QT Syndrome Secondary to Cesium Chloride Supplement
Vyas, Himeshkumar, Johnson, Katya, Houlihan, Robert J., Bauer, Brent A. , Ackerman, Michael J.

Mayo Clinic

The Journal of Alternative and Complementary Medicine | January 9, 2007 | Volume: 12 | Issue: 10 | Pages: 1011-1014

10.1089/acm.2006.12.1011 | PMID 17212573 Get It

Polyp Measurement with CT Colonography: Multiple-Reader, Multiple-Workstation Comparison
Young, Brett M., Paulsen, S, Booya, Fargol, Johnson, C. Daniel, Melton, Zackary, Rodysill, Drew, Mandrekar, Jay , Fletcher, Joel G. , Johnson, Kristina T.

Mayo Clinic

American Journal of Roentgenology | December 19, 2006 | Volume: 188 | Issue: 1 | Pages: 122-129

10.2214/ajr.05.1535 | PMID 17179354 Get It

Development of a Cathartic-Free Colorectal Cancer Screening Test Using Virtual Colonoscopy: A Feasibility Study
Carston, Michael J., Wentz, Robert J., Anderson, Steven M. , Johnson, C. Daniel, Johnson, Kristina T. , Manduca, Armando

Mayo Clinic

American Journal of Roentgenology | December 19, 2006 | Volume: 188 | Issue: 1 | Pages: W29-W36

10.2214/ajr.05.1484 | PMID 17179324 Get It

Phase III Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone: NCCTG N03C5
Loprinzi, Charles L. , Kugler, John W., Barton, Debra L. , Dueck, Amylou C. , Tschetter, Loren K., Nelimark, Robert A., Balcueva, Ernie, Burger, Kelli N. , Novotny, Paul J. , Carlson, Mark D., Duane, Steven F., Corso, Steven, Johnson, David B., Jaslowski, Anthony J., Dueck, A. C.

Mayo Clinic

Journal of Clinical Oncology | December 5, 2006 | Volume: 25 | Issue: 3 | Pages: 308-312

10.1200/jco.2006.07.5390 | PMID 17146104 Get It

Purpose Despite the utility of newer antidepressants for alleviating hot flashes, antidepressants do not work adequately enough in many patients. Gabapentin is a nonhormonal agent that also can reduce hot flashes. No data have been available to address whether the combination of both agents would more effectively alleviate hot flashes, compared with gabapentin alone, in patients with inadequate hot flash control with an antidepressant alone. Patients and Methods This was a randomized trial in which 118 patients with inadequate hot flash control on an antidepressant were randomly assigned to receive both an antidepressant and gabapentin versus being weaned off the antidepressant and receiving gabapentin alone. Patients were observed for 5 weeks (including a baseline week in which patients continued on their current antidepressant without gabapentin) during which time they completed validated daily hot flash diaries. Results Ninety-one patients provided complete data at the 5-week assessment. Regardless of whether or not the antidepressant was continued when gabapentin was started, there was an approximately 50% median reduction in hot flash frequencies (54%; 95% CI, 34% to 70% for combined treatment v 49%; 95% CI, 26% to 58% for gabapentin alone) and scores (56%; 95% CI, 26% to 71% for combined treatment v 60%; 95% CI, 33% to 73% for gabapentin alone). Conclusion Gabapentin seems to decrease hot flashes by approximately 50% in women with inadequate hot flash control who were using an antidepressant. This study saw no significant additional hot flash reduction from continuation of the antidepressant.
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Gojo, Ivana , Feldman, Eric J. , Greer, Jacqueline M., Bruzek, Laura M., Morris, Lawrence E. , Park, Youn, Adjei, Alex A. , Greenberg, Peter L. , Wright, John J., Karp, Judith E. , Lancet, Jeffrey E. , Gotlib, Jason , Liesveld, Jane L. , Kaufmann, Scott H. , Garrett‐Mayer, Elizabeth , Wright, John J.

Mayo Clinic

Blood | November 3, 2006 | Volume: 109 | Issue: 4 | Pages: 1387-1394

10.1182/blood-2006-04-014357 | PMID 17082323 Get It

AbstractOutcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML. The median age was 74 years, and a majority of patients had antecedent myelodysplastic syndrome. Complete remission (CR) was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in 15 patients, for an overall response rate of 23%. The median duration of CR was 7.3 months and the median survival of complete responders was 18 months. Adverse karyotype, age 75 years or older, and poor performance status correlated negatively with survival. Early death in the absence of progressive disease was rare, and drug-related nonhematologic serious adverse events were observed in 74 patients (47%). Inhibition of farnesylation of the surrogate protein HDJ-2 occurred in the large majority of marrow samples tested. Baseline levels of phosphorylated mitogen-activated protein kinase and AKT did not correlate with clinical response. Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response.
Aqueous Humor Outflow: What Do We Know? Where Will It Lead Us?
Fautsch, Michael P. , Ethier, C. Ross , Bhattacharya, Sanjoy K. , Johnson, Douglas H. , Bhattacharya, Sanjoy K

Mayo Clinic

Investigative Opthalmology & Visual Science | September 26, 2006 | Volume: 47 | Issue: 10 | Pages: 4181

10.1167/iovs.06-0830 | PMID 17003404 Get It

Anesthesia in Stevens–Johnson Syndrome: Report of a Case
Cucchiara, Roy F., Dawson, Brian

Mayo Clinic

Anesthesiology | September 25, 2006 | Volume: 35 | Issue: 5 | Pages: 537-539

10.1097/00000542-197111000-00016 | PMID 5098706 Get It

Regression analysis for comparing protein samples with 16O/18O stable-isotope labeled mass spectrometry
Eckel‐Passow, Jeanette E. , Oberg, Ann L. , Therneau, Terry M. , Mason, Christopher J. , Johnson, Kenneth L. , Bergen, H. Robert, Mahoney, Douglas W. , Olson, Janet E.

Mayo Clinic

Bioinformatics | September 6, 2006 | Volume: 22 | Issue: 22 | Pages: 2739-2745

10.1093/bioinformatics/btl464 | PMID 16954138 Get It

Abstract Motivation: Using stable isotopes in global proteome scans, labeled molecules from one sample are pooled with unlabeled molecules from another sample and subsequently subjected to mass-spectral analysis. Stable-isotope methodologies make use of the fact that identical molecules of different stable-isotope compositions are differentiated in a mass spectrometer and are represented in a mass spectrum as distinct isotopic clusters with a known mass shift. We describe two multivariable linear regression models for 16O/18O stable-isotope labeled data that jointly model pairs of resolved isotopic clusters from the same peptide and quantify the abundance present in each of the two biological samples while concurrently accounting for peptide-specific incorporation rates of the heavy isotope. The abundance measure for each peptide from the two biological samples is then used in down-stream statistical analyses, e.g. differential expression analysis. Because the multivariable regression models are able to correct for the abundance of the labeled peptide that appear as an unlabeled peptide due to the inability to exchange the natural C-terminal oxygen for the heavy isotope, they are particularly advantageous for a two-step digestion/labeling procedure. We discuss how estimates from the regression model are used to quantify the variability of the estimated abundance measures for the paired samples. Although discussed in the context of 16O/18O stable-isotope labeled data, the multivariable regression models are generalizable to other stable-isotope labeled technologies. Contact: eckel@mayo.edu